Form 4: Solenos CDO Manher Joshi Receives Equity Compensation

Solenos Chief Development Officer Manher Joshi reported the acquisition of restricted stock units and employee stock options as part of his compensation package.

Summary

• Manher Joshi, Chief Development Officer of SOLENO THERAPEUTICS INC (SLNO), reported changes in his beneficial ownership of company securities.
• Joshi acquired 4,100 restricted stock units (RSUs) on January 21, 2026, which represent a contingent right to receive one share of Common Stock each.
• These 4,100 RSUs are scheduled to vest 100% on December 15, 2027, provided Joshi continues as a Service Provider.
• Following this transaction, Joshi beneficially owns a total of 20,171 restricted stock units.
• Additionally, Joshi acquired 4,700 employee stock options (right to buy) on January 21, 2026, with an exercise price of $43.65 per share.
• These stock options will vest at a rate of 1/48th of the total shares on February 1, 2026, and on each subsequent one-month anniversary, subject to continued service.
• The employee stock options have an expiration date of January 21, 2036.
• The filing indicates these transactions were made pursuant to a Rule 10b5-1(c) plan.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While it's a routine compensation disclosure and not directly indicative of operational performance, the grant of equity to a key executive like the Chief Development Officer is generally viewed positively as it aligns management's interests with long-term shareholder value and aids in executive retention. There are no negative implications from this specific filing.

Positives

• The grant of 4,100 restricted stock units and 4,700 employee stock options aligns the Chief Development Officer's interests with long-term shareholder value.
• Equity compensation serves as a retention mechanism for key executives, ensuring continuity in leadership.

Future Outlook

The filing details future vesting schedules for both restricted stock units (December 15, 2027) and employee stock options (monthly vesting starting February 1, 2026, over 48 months), contingent on the reporting person's continued service.

Industry Context

This filing represents a routine executive compensation event within the biotechnology or pharmaceutical industry, where equity grants are a standard component of executive pay packages designed to incentivize long-term performance and retention. Such grants are common across publicly traded companies, particularly in sectors with high R&D costs and long development cycles like therapeutics, to align management incentives with shareholder value creation over extended periods.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) and employee stock options as a significant component of executive compensation is a common practice across the U.S. public company landscape, particularly in growth-oriented sectors like biotechnology.
• Vesting schedules, such as the 100% vesting on a future date for RSUs and monthly vesting over several years for options, are standard mechanisms to ensure executive retention and align incentives with long-term company performance, comparable to practices at peers like BioNTech or Moderna for their key scientific and development officers.
• The disclosure of these grants under a Rule 10b5-1(c) plan indicates a pre-arranged compensation structure, which is a best practice for managing insider trading concerns and providing transparency.

Stakeholder Impact

• Shareholders: Potential for future dilution upon vesting and exercise of RSUs and options, but also benefits from incentivized executive performance and retention.
• Employees (specifically Manher Joshi): Significant increase in long-term equity compensation, aligning personal financial interests with company success and providing a strong incentive for continued service.

Next Steps

• The 4,100 restricted stock units will vest on December 15, 2027, subject to continued service.
• The 4,700 employee stock options will begin vesting on February 1, 2026, with 1/48th vesting monthly thereafter, subject to continued service.

Key Dates

Keywords

SOLENO THERAPEUTICS, SLNO, Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, RSU, Stock Option, Executive Compensation, Manher Joshi, Chief Development Officer